Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 67   

Articles published

PFE 34.77 +0.45 (1.31%)
price chart
Merck, Pfizer Back Lawmakers Who Oppose Company Products
In addition to Johnson & Johnson, Phrma members Pfizer Inc., Bayer AG, and Merck & Co. Inc. sell birth-control products such as estrogen, IUDs or so-called morning after pills known as Plan B, according to IMS Health, a health-care information and ...
Related articles »  
FDA Recommendations Bode Well For Pfizer
Pfizer (NYSE:PFE) is still transitioning itself after its best selling drug Lipitor went off patent in 2011. Also starting in July a marketing partnership between Amgen and Pfizer ends which will result in a large loss of revenue from the blockbuster ...
Pfizer's Arthritis Pill Raises Safety Concerns, FDA Staff Says  Bloomberg
FDA Staff Raises Concerns About Arthritis Drug  New York Times
Related articles »  
Goodbye, Lipitor. Pfizer Bids a Farewell
Pfizer officials told The Wall Street Journal that the company is no longer negotiating new contracts to sell Lipitor to health plans, which are signing up to sell generic versions at far lower prices.
Related articles »  
Dow Chemical taking Pfizer space
COLLEGEVILLE �Dow Chemical Co. has finalized a long-term lease on 800,000 square feet of space at Pfizer Inc.'s campus here in what is one of the largest lease deals to be struck in the suburban office market.
Fortune 500: Pfizer drops to No. 40 in 2012 rankings
Pfizer sign AP/FILEPfizer came in at No. 40 on the Fortune 500, the only major employer in Southwest Michigan to break the Top 50 of the annual rankings.
Related articles »  
Pfizer Names Olivier Brandicourt as President and General Manager, Emerging ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) named Olivier Brandicourt as President and General Manager of the Emerging Markets and Established Products Business Units, effective June 1, 2012.
PPD names new CEO  StarNewsOnline.com
PPD Names David Simmons Chairman and CEO  WWAY NewsChannel 3
Related articles »  
Amylin Said to Attract Interest From Pfizer, AstraZeneca
May 15 (Bloomberg) -- Amylin Pharmaceuticals Inc. has lured suitors such as Pfizer Inc., AstraZeneca Plc and Sanofi, which signed confidentiality agreements on the drugmaker's sale process, said people familiar with the matter.
Related articles »  
Pfizer's Arthritis Pill Backed by U.S. FDA Advisory Panel
May 9 (Bloomberg) -- Pfizer Inc.'s experimental pill to treat rheumatoid arthritis, one of the drugmaker's leading therapy candidates, should be approved by U.S.
Tofacitinib: FDA Panel Backs Rheumatoid Arthritis Drug  Huffington Post
New rheumatoid arthritis pill tofacitinib backed by FDA panel  CBS News
Related articles »  
Pfizer: Alzheimer's Drugs Will Carry Stock To New Highs In 2013
There is a strong market for any drug that can mitigate or even delay the effects of Alzheimer's disease, and if Pfizer became the first company with a drug to market for Alzheimer's disease I think the news could bring Pfizer stock to new highs ...
Pfizer Axes Late-Stage Lyrica Study Following Disappointing Results  Fox Business
Pfizer Reports Subpar Lyrica Phase 3 Results  dailyRx
Related articles »  
Preview: U.S. panel seen backing Pfizer's arthritis drug hope
WASHINGTON (Reuters) - Pfizer Inc's experimental rheumatoid arthritis drug goes before an advisory panel next week, a potential blockbuster medicine that would revive faith in the company's research if its benefits are deemed to outweigh its side effects.
Related articles »